Although ibrutinib (and other BTK inhibitors) can induce dramatic clinical responses in CLL patients, combinations of signaling inhibitors may be an effective strategy to boost responses and reduce the incidence of development of resistance and/or transformation to high grade disease [28]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.